Literature DB >> 8315426

Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial.

J M Vose1, E C Reed, G C Pippert, J R Anderson, P J Bierman, A Kessinger, J Spinolo, J O Armitage.   

Abstract

PURPOSE: To compare the use of intravenous (IV) hydration plus either continuous bladder irrigation or mesna for the prevention of hemorrhagic cystitis in the bone marrow transplant setting. PATIENTS AND METHODS: Two hundred patients were prospectively randomized to receive either continuous bladder irrigation with 200 mL/h of normal saline, or continuous infusion mesna at 100% of the cyclophosphamide dose.
RESULTS: The overall incidence of hematuria of any grade was significantly higher in the bladder-irrigation group (76%) compared with the mesna group (53%) (P = .007). However, the incidence of grade III and IV hematuria was the same in both groups (18%; P = NS). Moderate or severe discomfort or bladder spasms were reported in 84% of the patients who received bladder irrigation, compared with 2% of the patients who received mesna prophylaxis (P < .0001). Urinary tract infections (UTIs) were documented in 27% of the patients in the bladder-irrigation group, compared with 14% of the patients in the mesna group (P = .03).
CONCLUSION: Both continuous bladder irrigation and mesna were equally effective in preventing severe hemorrhagic cystitis associated with high-dose cyclophosphamide and bone marrow transplantation. However, the use of mesna was associated with significantly less discomfort and a lower incidence of UTIs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315426     DOI: 10.1200/JCO.1993.11.7.1306

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

1.  Improvised urinary bladder irrigation system.

Authors:  Akhilesh K R Agarwal; Aakash Bora; Ambar Banerjee
Journal:  Ann R Coll Surg Engl       Date:  2008-10       Impact factor: 1.891

Review 2.  Chemical hemorrhagic cystitis: Diagnostic and therapeutic pitfalls (Review).

Authors:  Razvan-Cosmin Petca; Razvan-Ionut Popescu; Cristian Toma; Mihai Cristian Dumitrascu; Aida Petca; Florica Sandru; Calin Bogdan Chibelean
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

3.  Interventions to treat hemorrhagic cystitis: a systematic review and meta-analysis.

Authors:  Claudia Milena Pitto; Herney Andrés García-Perdomo
Journal:  Support Care Cancer       Date:  2017-05-01       Impact factor: 3.603

4.  Predictors of the development of surgical complications among hematopoietic stem cell transplantation recipients.

Authors:  Iyad Anabtawi; Fawzi Abdelrahman; Ahamd Alomari; Murad Ba'ba'; Mahmoud Al Masri
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

Review 5.  Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide.

Authors:  Deborah Robinson; Ginny Schulz; Rachel Langley; Kevin Donze; Kari Winchester; Cheryl Rodgers
Journal:  J Pediatr Oncol Nurs       Date:  2014-05-05       Impact factor: 1.636

6.  Curing lupus--views from the foothills.

Authors:  J H Klippel
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

Review 7.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

8.  Hemorrhagic cystitis: A challenge to the urologist.

Authors:  R Manikandan; Santosh Kumar; Lalgudi N Dorairajan
Journal:  Indian J Urol       Date:  2010-04

9.  Reactive Carbonyl Species Scavengers-Novel Therapeutic Approaches for Chronic Diseases.

Authors:  Sean S Davies; Linda S Zhang
Journal:  Curr Pharmacol Rep       Date:  2017-02-14

Review 10.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.